TransMedics Group (NASDAQ:TMDX) Posts Quarterly Earnings Results, Misses Estimates By $0.32 EPS

TransMedics Group (NASDAQ:TMDX) released its quarterly earnings data on Tuesday. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.32), FiscalAI reports. TransMedics Group had a net margin of 31.43% and a return on equity of 30.17%. The company had revenue of $173.93 million for the quarter, compared to analysts’ expectations of $174.48 million. During the same period in the previous year, the firm earned $0.70 earnings per share. The firm’s revenue for the quarter was up 21.2% on a year-over-year basis.

Here are the key takeaways from TransMedics Group’s conference call:

• Q1 results were strong — revenue was $174 million (?21% YoY, 8% sequential), adjusted operating profit was ~$18.1M (~10% margin), and the company ended the quarter with ~$462M in cash.
• CHOPS and clinical path forward — TransMedics unveiled CHOPS as a regulated cold?storage device that will serve as the control arm for ENHANCE/DENOVO; an IDE supplement will be filed in weeks with approval and implementation expected in early Q3 2026 and a later 510(k) for commercial use planned.
• Major product and geographic expansion — the company is advancing OCS Kidney on its Gen 3.0 platform (final design shown late June; targeting a U.S. IDE in early 2027), upgrading heart/lung/liver to Gen 3.0, and building a European NOP/logistics network via a PAD Aviation partnership to expand TAM.
• Revenue outlook reiterated — management reaffirmed full?year 2026 revenue guidance of $727M–$757M (20%–25% growth), citing continued OCS/NOP volume and international expansion as drivers.
• Near?term margin and enrollment risks — gross margin fell to ~58% (down ~331 bps YoY) and adjusted operating expenses rose ~42% YoY as the company is heavily investing in R&D, NOP expansion and supply?chain inventory; additionally, donor volumes remain volatile amid U.S. transplant modernization, which could pressure near?term growth and margins.

TransMedics Group Trading Down 2.2%

TransMedics Group stock opened at $94.93 on Wednesday. TransMedics Group has a 12-month low of $91.01 and a 12-month high of $156.00. The firm has a market capitalization of $3.28 billion, a price-to-earnings ratio of 19.37 and a beta of 2.07. The firm has a 50 day moving average of $116.57 and a 200 day moving average of $125.96. The company has a current ratio of 7.14, a quick ratio of 6.59 and a debt-to-equity ratio of 1.06.

Insiders Place Their Bets

In related news, CFO Gerardo Hernandez sold 7,236 shares of TransMedics Group stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $147.21, for a total transaction of $1,065,211.56. Following the transaction, the chief financial officer owned 14,689 shares in the company, valued at approximately $2,162,367.69. The trade was a 33.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Anil P. Ranganath sold 864 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total transaction of $120,199.68. Following the completion of the transaction, the insider directly owned 13,091 shares of the company’s stock, valued at $1,821,219.92. This represents a 6.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 16,205 shares of company stock valued at $2,353,002. Insiders own 6.90% of the company’s stock.

Institutional Trading of TransMedics Group

Several institutional investors have recently made changes to their positions in TMDX. Parallel Advisors LLC raised its position in shares of TransMedics Group by 42.1% during the fourth quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after buying an additional 83 shares during the last quarter. Canada Pension Plan Investment Board raised its position in shares of TransMedics Group by 2.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock valued at $482,000 after buying an additional 100 shares in the last quarter. US Bancorp DE lifted its holdings in shares of TransMedics Group by 24.2% in the 3rd quarter. US Bancorp DE now owns 533 shares of the company’s stock valued at $60,000 after acquiring an additional 104 shares during the last quarter. Smartleaf Asset Management LLC grew its position in TransMedics Group by 24.5% in the second quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock worth $72,000 after acquiring an additional 108 shares in the last quarter. Finally, Summit Global Investments raised its position in TransMedics Group by 3.6% during the fourth quarter. Summit Global Investments now owns 3,260 shares of the company’s stock valued at $397,000 after purchasing an additional 112 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Trending Headlines about TransMedics Group

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Q1 revenue grew 21.2% year?over?year to $173.9M, indicating continued demand expansion for TransMedics’ organ?preservation systems and consumables. TransMedics Reports First Quarter 2026 Financial Results
• Positive Sentiment: Profitability remains strong on reported metrics: net margin ~31.4% and ROE ~30.2%, which signal healthy unit economics and operational leverage as revenue scales. MarketBeat Q1 Summary & Materials
• Neutral Sentiment: Management issued FY-2026 revenue guidance of $727M–$757M (consensus ~$739M). The range includes the Street estimate but is wide, leaving room for investor interpretation on pacing and margin assumptions. Guidance Update (company release/slides)
• Neutral Sentiment: Company provided supporting materials (press release, slide deck, and conference call transcript) that investors can review for detail on regional trends, disposable attach rates, and cadence of system placements. Earnings Call Transcript
• Negative Sentiment: Q1 EPS missed materially: $0.30 vs. consensus ~$0.62, and down from $0.70 a year ago — this earnings miss drove near?term investor disappointment. Zacks: Q1 Earnings and Revenues Miss Estimates
• Negative Sentiment: Revenue was a slight miss versus consensus ($173.93M vs. ~$174.5M), reinforcing the EPS shortfall and prompting questions about near?term margin or timing issues. Zacks: What Key Metrics Have to Say

Wall Street Analyst Weigh In

TMDX has been the subject of a number of research reports. Wall Street Zen lowered shares of TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. JPMorgan Chase & Co. raised their target price on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Piper Sandler upped their price target on shares of TransMedics Group from $140.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Oppenheimer lowered shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Finally, TD Cowen reaffirmed a “buy” rating on shares of TransMedics Group in a report on Monday, March 16th. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus price target of $148.78.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post?transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.